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Systemic sclerosis (SSc) is a systemic rheumatic disease with poor prognosis since therapeutic options are limited. Recent evidence
from animal models suggests that B-cells may be actively involved in the ﬁbrotic process. B-cells from tight skin mice, an animal
model of scleroderma, display a “hyperresponsive” phenotype; treatment with rituximab (RTX) signiﬁcantly attenuates skin
ﬁbrosis in this animal model. In humans, B-cell inﬁltration is a prominent ﬁnding in most lung biopsies obtained from patients
with SSc-associated interstitial lung disease. Several open label studies have assessed the clinical eﬃcacy of RTX in SSc. In most
patients skin ﬁbrosis improved; lung function either improved or remained stable. Deﬁnite conclusions regarding the clinical
eﬃcacy of RTX in SSc cannot be drawn but further exploration with a multicenter, randomized study is warranted.
1.Introduction
Systemic sclerosis (SSc) is a systemic rheumatic disease
characterized by vasculopathy, autoimmunity, and ﬁbrosis.
The available therapeutic options are extremely limited and
prognosis is variable. Cyclophosphamide (CYC) has shown
modest eﬃcacy in the treatment of SSc-associated interstitial
lung disease (ILD) [1] but its long-term use is accom-
panied by signiﬁcant toxicity. Therefore, novel therapeutic
approaches are desperately needed. During the last decade,
B-cell depletion by rituximab (RTX), a monoclonal antibody
that targets B-cells, has emerged as a promising therapy for
a wide range of systemic autoimmune diseases. It has been
approved for the treatment of rheumatoid arthritis but it has
also been tried in systemic lupus erythematosus [2], systemic
vasculitides [3], and multiple sclerosis [4], among others. An
expanding body of experimental evidence suggests that B-
cells play a role in the ﬁbrotic process, raising the question
of whether B-cell depletion might be a potential therapeutic
approach in SSc [5–8]. During the last 2 years, 4 small-scale,
open-label studies and a few case reports have addressed this
question to some extent, reporting encouraging results. In
this paper we provide the experimental evidence supporting
the active role of B-cells in ﬁbrosis and summarize all
the available clinical evidence regarding the use of RTX in
patients with SSc.
2. Methods
We performed a literature search in PubMed from 1995 and
onwards.Weusedthefollowingkeywords:systemicsclerosis,
scleroderma, rituximab, B-cells, ﬁbrosis, ILD, and therapy in
various combinations.
3. Results
3.1. The Role of B Cells in Fibrosis: Experimental Evidence
3.1.1. Animal Models. Research in SSc has been problematic
due to the low prevalence of the disease and the lack of
an animal model that possesses all features of the human
disease. Nevertheless, the tight skin mouse (TSK) and the2 International Journal of Rheumatology
bleomycin (BLM) induced mouse model of SSc have been
extensively used as animal models of the disease. TSK mice
are characterized by extensive skin ﬁbrosis and immunolog-
ical abnormalities including the presence of autoantibodies
to topoisomerase-1, both reminiscent of those observed in
the human disease [9]. A lot of research has been done
on the potential role of B-cells in this animal model. It
has been reported that TSK B-cells exhibit enhanced CD19
signaling compared to WT B-cells, although the expression
of this molecule was similar in TSK and WT B-cells [10].
CD19 is a membrane glycoprotein of the immunoglobulin
superfamily and part of the hetero-oligomeric complex
comprisingthecomplementreceptortype2,whichpositively
regulates BCR activation. The authors reported enhanced
CD19 tyrosine phosphorylation by 45% compared to WT
B-cells. Tyrosine phosphorylation of Vav and Lyn kinase,
both of which are important downstream steps of CD19
signaling, was also found to be enhanced by 3.4-fold and
22%respectively,comparedtoWTB-cells.CytoplasmicCa+2
responses,generatedbyCD19ligation,werealsosigniﬁcantly
augmented in TSK B-cells compared to WT B-cells. The
crucial role of CD19 signaling in this animal model is
underscored by the fact that CD19 deﬁciency normalizes the
“hyper responsive” phenotype of TSK B-cells and leads to a
signiﬁcant improvement of skin ﬁbrosis compared to control
TSK mice. The above data suggest that B-cell hyperactivity
and ﬁbrosis are somehow linked in this animal model and
raise the question of whether targeting B-cells might be an
eﬀective way of attenuating ﬁbrosis.
In another study by Asano et al., the eﬀect of enforced
CD19 overexpression on B-cells in the TSK mouse model
was assessed [11]. CD19 transgenic TSK mice exhibited
increasedautoAbproductioncomparedtocontrolTSKmice.
More speciﬁcally, CD19 transgenic mice that expressed 20%
higherlevelsofCD19(CD19TG4+/−)and200%higherlevels
(CD19 TG1+/+) exhibited increased antitopoisomerase-1
levelsby7.9-foldand20-fold,comparedtocontrolTSKmice,
respectively. Despite this increase in autoAb production,
CD19 overexpression did not lead to worsening of skin
ﬁbrosis compared to control TSK mice. The authors also
focused on gaining further insight into the hyperactive
phenotype of the TSK B-cell and found that this can
relate to a defective CD22 signaling, an important negative
BCR response regulator. Upon stimulation, CD22 tyrosine
phosphorylation was 58% lower in TSK B-cells compared to
WT B-cells. The hypophosphorylation of CD22 coincided
with the hyperphosphorylation of CD19, which led the
investigatorstosuggestthatdefectiveCD22signalingleadsto
increased CD19 signaling which is, at least partially, respon-
sible for the hyperresponsive phenotype of the TSK B-cell.
Recently it was reported that TSK mice have autoanti-
bodies agaist CD22 which were found to be functional and
able to attenuate CD22 activation [12]. Since CD22 inhibits
B-cell activation, these autoAbs may contribute to the
“overactivated” phenotype of TSK B-cells. In other words,
TSK B-cells produce an autoAb that enhances their own acti-
vation, something that may have pathogenic implications.
Once the link between B-cell hyperactivity and ﬁbrosis
had been established in the TSK mouse, the next logical step
would be to assess the eﬀect of B-cell depletion in this animal
model. RTX administration to newborn TSK mice led to a
signiﬁcant attenuation of skin ﬁbrosis by 43% compared to
control TSK mice accompanied by a signiﬁcant reduction
in autoantibody production [13]. When the same treatment
was applied in 56-day old TSK mice, which are characterized
by established skin ﬁbrosis, skin thickening was not reduced,
compared to TSK control mice. These data suggest that B-
cells may be more important in the early phase of the disease
but less so in established disease. It is noteworthy that B-
cells are not present in the skin of TSK mice, indicating that
their contribution to skin ﬁbrosis may be indirect. Despite
the improvement of skin thickening, B-cell depletion had
no eﬀect on the lung disease of TSK mice, indicating that
diﬀerent manifestations are probably mediated by diﬀerent
pathogenic mechanisms in this animal model. Another
study explored the eﬀects of B-cell survival factor (BAFF)
inhibition in TSK mice and reported improvement of skin
ﬁbrosis and attenuation of autoAb production [14]. All these
data underline the key role of B-cells in the ﬁbrotic process
in this animal model.
The role of B-cells in ﬁbrosis has also been explored
in the BLM-induced mouse model of SSc. Besides skin
involvement, lung ﬁbrosis is a prominent feature of this
animal model, making it suitable for the assessment of a
giventreatmentonILD.TheinvestigatorsreportedthatBLM
administration to CD19 knockout mice led to diminished
skin thickening compared to BLM-treated WT littermates
[15]. More importantly, CD19 deﬁciency led to attenuation
of BLM-induced lung ﬁbrosis, indicating that B-cells may be
actively involved in the ﬁbrotic process not only in the skin
but in the lung as well.
Recently, the role of CD19 during the development of
pulmonary ﬁbrosis in the BLM-induced model has been
extensively assessed [16]. Mice either lacking or overexpress-
ing CD19 were treated with intratracheal injections of BLM.
It was reported that CD19 knockout mice exhibited less
lung ﬁbrosis in sharp contrast to mice overexpressing CD19
which showed augmented lung ﬁbrosis compared to WT
littermates. Interestingly, CD19 expression correlated with
the number of B-cells in the bronchoalveolar lavage ﬂuid;
CD19 deﬁciency inhibited the accumulation of B-cells in the
alveolar compartment following BLM challenge. The above
data indicate that CD19 plays a crucial role in pulmonary
ﬁbrosis in this mouse model.
Research on animal models of scleroderma has provided
evidence indicating a potential link between B-cell hyper-
activity and ﬁbrosis. However, we should note that SSc is a
far more complex disease and therefore these data cannot be
directly extrapolated to humans.
3.1.2. Humans. Only a few studies have addressed the pot-
ential contribution of B-cells in the pathogenesis of SSc. In
one such study, it was reported that B-cells from patients
with SSc had 20% higher CD19 expression compared to
B-cells from healthy subjects [17]. Detailed phenotypic
characterization of B-cells from patients with SSc revealed
that peripheral blood B-cells were increased in patients
with SSc compared to healthy subjects [18]. Naive B-cellsInternational Journal of Rheumatology 3
were reported to be increased in patients with SSc whereas
memoryB-cellsandplasmablastswerereduced,comparedto
healthy subjects. Memory B-cells from patients with SSc had
increased expression of several activation markers, including
CD95 and were prone to spontaneous apoptosis. These data
indicate that B-cell homeostasis in SSc is disturbed.
Since patients with SSc express higher levels of CD19 on
B-cells and since CD19 is a key molecule in the regulation
of signaling thresholds in these cells, something that may
relate to break of tolerance and induction of autoimmunity,
investigators explored the mechanisms involved in CD19
overexpression in SSc B-cells. Tsuchiya et al. explored the
potential association of CD19 polymorphisms with SSc and
the level of CD19 expression on B-cells [19]. They reported
a signiﬁcant association between the −499T allele in the
promoter region of the CD19 gene with SSc, with an odds
ratio of 2.18; carriers of this allele exhibited signiﬁcantly
higher CD19 levels on B-cells compared to noncarriers.
These data raise the question of whether CD19 upregulation
in SSc B-cells is genetically determined.
It is not clear why SSc B-cells exhibit such an “overacti-
vated” phenotype; B-cell survival factors may be implicated.
It has been reported that BAFF serum levels are higher
in patients with SSc compared to healthy controls (P<
0.001) [20]. Furthermore, patients with the diﬀuse form
had signiﬁcantly increased levels compared to patients with
the limited form of the disease. Nevertheless, this was not
a disease-speciﬁc ﬁnding, since patients with SLE or DM
had similarly increased levels. Patients with SSc, exhibiting
increased serum BAFF levels tended to have more severe
skin ﬁbrosis as assessed by the MRSS tool (P<0.01),
worse FVC values (P<0.05) and higher ESR (P<0.05).
Furthermore, decreasing serum BAFF levels were associated
with attenuation of skin ﬁbrosis, whereas increasing levels
correlated with clinical worsening. The expression of BAFF
in the skin at the mRNA level was found to be increased in
early disease. Moreover, upregulation of the BAFF receptor
was reported on B-cells from patients with SSc compared to
healthysubjects.ItisalsoworthmentioningthatB-cellsfrom
patients with SSc stimulated with BAFF produced 38% more
IL-6, a cytokine able to stimulate ﬁbroblasts, compared to B-
cell from healthy subjects.
In a recent study it was found that peripheral blood
mononuclear cells (PBMCs) from SSc patients produced
signiﬁcantly more APRIL (a proliferation inducing ligand),
a B-cell survival factor, compared to PBMCs from healthy
subjects (P<0.01) [21]. This increase was associated
with more severe disease manifestations. These data indicate
that upregulation of B-cell survival factors may contribute
to B-cell hyperactivity and autoimmunity in SSc. BAFF
and APRIL emerge as two interesting therapeutic targets;
inhibition of these molecules may modulate B-cell function
in SSc and potentially lead to clinical beneﬁt.
An interesting study, performed by Whitﬁeld et al.
examined gene expression proﬁle, using microarrays in
scleroderma skin compared to normal [22]. The authors
found that genes characteristic of B-cells, ﬁbroblasts and
endothelial cells were diﬀerentially expressed in scleroderma
compared to normal skin. Interestingly, the same expression
pattern was evident in patients with SSc in both clinically
involved as well as uninvolved skin, underscoring the
systemic nature of the disease. Since endothelial cells and
ﬁbroblasts are considered key players in SSc, these data point
towards a potentially active role of B-cells in skin ﬁbrosis.
The potential role of B-cells in SSc-associated ILD has
been inadequately investigated. It has been reported that B-
cells are present in lung biopsies from patients with SSc-
associated ILD [23] and that plasma cell inﬁltration of the
alveolar walls is an early ﬁnding [24].
The above studies have documented the presence of B-
cells in both skin and lung of patients with SSc. However
direct evidence of a pathogenetic role is lacking.
3.2. B-Cell Depletion in SSc: Update on Clinical Evidence.
There are 4 small-scale, open-label clinical studies exploring
the potential clinical eﬃcacy of RTX in SSc, including one
from our research group and a few case reports. In the ﬁrst
study by Smith et al., eight patients with early (deﬁned by
disease duration of <4 years from the ﬁrst non-Raynaud’s
disease manifestation) diﬀuse SSc received a single course
of RTX (consisting of 2 infusions, 1000mg each, at day 1
and 15) [25]. Patients were evaluated clinically at 24 weeks
and subjected to skin biopsies at baseline and 12 weeks.
Five patients had evidence of mild ILD; patients with severe
ILD were excluded from the study. Improvement of skin
thickening was reported as assessed by the MRSS tool (mean
±SD:24.8 ±3.4versus14.3 ±3.5atbaselineversus24weeks
resp., P<0.001). It is worth mentioning that improvement
of skin thickening was veriﬁed at the histological level,
since both collagen and myoﬁbroblast score were reduced
signiﬁcantly following treatment (P = 0.014 and P = 0.013,
resp.). Half of the patients had evidence of B-cell inﬁltration
in their skin; treatment eﬀectively depleted these cells.
Lung function tests, systolic pulmonary artery pressure, left
ventricular ejection fraction, creatinine clearance, and HAQ
score remained stable throughout the study. Two serious
events were reported (one patient underwent coronary
artery bypass surgery and another was hospitalized due
to low-grade fever that spontaneously subsided) but were
considered to be probably unrelated to study drug. This is
the ﬁrst study that provides clinical as well as histological
evidence that RTX treatment may favourably aﬀect skin
ﬁbrosisinSSc.Itshouldbenotedhowever,thatthisstudyhas
potentiallimitationswhicharetherelativelysmallnumberof
patients recruited and the lack of a control arm. Resolution
of skin ﬁbrosis is associated with the natural course of
the disease, therefore uncontrolled studies are diﬃcult to
interpret. Nevertheless, the improvement of skin ﬁbrosis
reported in this study was quite signiﬁcant, which makes
it rather unlikely to have occurred spontaneously, especially
within the limited time frame of the study.
Another study reported the eﬀects of a single course
of RTX treatment in 15 patients with early (as deﬁned
by disease duration of <18 months from the ﬁrst non-
Raynaud’s disease manifestation) diﬀuse SSc [26]. Similar
to the study by Smith et al., only 7 out of 15 patients
had evidence of mild ILD, since the existence of moderate
or severe ILD was an exclusion criterion. Patients were4 International Journal of Rheumatology
clinically evaluated at 24 weeks and 1 year. In contrast to the
study by Smith et al., no improvement of skin thickening
as assessed by the MRSS, tool was reported (mean ± SD:
20.6 ± 4.4, 20.2 ± 5.5 and 21.1 ± 5.2 at baseline, 24wks,
and 48wks, respectively, P = ns). However, histologic
improvement was found; myoﬁbroblast score declined from
49.5 to 36.6 (P<0.05). Skin inﬁltrating B-cells were
signiﬁcantly increased in patients with SSc compared to
healthy controls who had no B-cells and were eliminated
posttreatment. Pulmonary function tests remained stable
at 24wks compared to baseline; it is noteworthy though
that FVC values increased by an average of 3.5% at 24wks
compared to pretreatment values, but the 95% CI was wide
and thus results were not statistically signiﬁcant. The authors
do not report PFTs at 1 year posttreatment. No evidence of
new or progressive major organ involvement was reported.
Treatment was well tolerated.
Our research group has performed an open label,
randomized controlled, 1-year pilot study, assessing the
eﬀect of RTX in SSc [27]. We recruited 14 patients with
SSc randomized as follows: 8 patients in the treatment
arm and 6 patients in the control arm of the study. All
patientshaddiﬀusedisease,wereanti-Scl70positive,andhad
evidenceofILD.Therewerenodiﬀerencesintermsofdisease
duration, baseline MRSS and baseline PFT’s between the
treatment and the control group. Patients in the treatment
arm received 2 cycles of RTX at baseline and 24 weeks (each
cycle consisting of 4 weekly RTX infusions (375mg/m2)).
We found a signiﬁcant improvement of both FVC (mean
± SD: 68.13 ± 19.69 versus 75.63 ± 19.73% of predicted
values, at baseline versus 1 year resp., P = 0.0018) and
DLco (mean ± SD: 52.25 ± 20.71 versus 62 ± 23.21% of
predicted values, at baseline versus 1 year, resp., P = 0.017)
in the treatment group whereas no change was noticed in
the control group. The median (upper and lower quartile
values) percentage of improvement of FVC in the RTX
group was 10.25% (6.19–18.65) whereas in the control
group FVC deteriorated (median percentage of deterioration
(upper and lower quartile values) 5.04% (4.11–11.6)). Direct
comparison of FVC changes recorded at 1 year, revealed that
the RTX-treated group improved signiﬁcantly (P = 0.002)
compared to the standard-treatment (control) group. The
median (upper and lower quartile values) percentage of
improvement of DLco in the RTX group was 19.46% (3.7–
30.8) whereas in the control group the median percentage of
deterioration was 7.5% (1.4–26.57) (P = 0.023).
Skin thickening, assessed with the MRSS, was similar in
the two treatment groups at baseline (P = 0.50). However
at the 1 year evaluation, there was a signiﬁcant decrease of
MRSS in the RTX group compared to the baseline score
(mean ± SD, 13.5 ± 6.84 versus 8.37 ± 6.45 at baseline
versus 1 year, resp., P = 0.0003). On the contrary, no
signiﬁcant change in skin scores was noticed in the control
group at 1 year when compared to the baseline MRSS
(mean ± SD, 11.50 ± 2.16 versus 9.66 ± 3.38 at baseline
versus 1-year, resp., P = 0.16). The median (upper and
lower quartile values) percentage of improvement in the
RTX-treated group was 39.25% (27.33–64.95) compared
to 20.80% (10.78–39.28) in the control group. Statistical
analysis revealed that diﬀerences tended to be but were not
statistically signiﬁcant (P = 0.06). Improvement of skin
ﬁbrosis was also documented at the histological level. We
found a signiﬁcant reduction of collagen deposition in the
papillary dermis at 24wk compared to baseline in patients
treated with RTX; histologic improvement correlated with
skin B-cell depletion. Histological data matched the clinical
data, since all patients showing histologic improvement also
improved clinically. One serious adverse event was reported
(respiratory tract infection); the patient recovered fully
following short-term hospitalization.
Even though this is the ﬁrst and only so far, randomized,
controlled study assessing the eﬃcacy of RTX in SSc,
several limitations exist. Firstly, the small number of patients
recruited does not provide the study with suﬃcient statistical
powertoproveeﬃcacy.Additionally,mostpatientshadlong-
standing disease since no disease duration restriction was
applied and was heterogeneous in terms of disease duration,
severity, and previous treatments.
Recently, one more study assessing the clinical eﬃcacy
of RTX in SSc was published [28]. Nine patients with SSc
were recruited and received one course of RTX (consisting
of 2 infusions, 1gr each). All patients had severe cutaneous
involvement and had experienced worsening of skin score
despite treatment with CYC. A signiﬁcant reduction of skin
thickening was reported with patients showing a median
decrease of skin score of 43.3% at 6 months compared to
baseline. Disease activity and severity index also declined.
PFTs remained stable throughout the study. A signiﬁcant
decline in IL-6 levels following treatment was also reported;
the authors hypothesized that this may have contributed to
attenuation of skin ﬁbrosis.
Three case reports have also appeared in the literature
regarding the use of RTX in SSc. The ﬁrst case describing
the beneﬁcial eﬀect of RTX on SSc-associated ILD was
reported by McGonagle et al. [29]. PFTs, musculoskeletal
manifestations and functional status improved following
treatment. However treatment eﬀect waned over time and
a second course of RTX was administered. PFTs improved
again; DLco increased from 34.3% to 48% of predicted
values. These data are in agreement with ours, showing that
consecutive treatment courses may be needed to augment
and sustain the eﬀect of RTX on pulmonary function.
The beneﬁcial eﬀect of RTX on SSc-associated ILD has
also been documented in a case report by our group [30].
Ourpatientwastreatedwith4consecutiveRTXcoursesevery
6 months and completed a followup of 2 years. PFTs signiﬁ-
cantly increased; FVC and DLco reached values of 35%, and
33%respectively,comparedto30%and14%ofpretreatment
values. Quantiﬁcation of ground glass lesions using a
computer-aided diagnosis system showed a 14% reduction.
Skin thickening improved as indicated by a decline in MRSS
from20to9.Clinicalimprovementcoincidedwithhistologic
improvement with reduction of collagen accumulation and
myoﬁbroblast score; skin inﬁltrating B-cells were eliminated
posttreatment.Thefunctionalstatusofthepatientimproved
as indicated by a decrease in HAQ score and an increase
in 6-minute walking distance. This was the ﬁrst report of
long-term RTX treatment in SSc. Recently, another case ofInternational Journal of Rheumatology 5
Table 1: Studies assessing the eﬃcacy of RTX in SSc.
Outcomes
Skin Lung
function
tests
Functional
status
Study Number of
participants Study type Evaluation time
point(months)
Number of
RTX
courses
Clinical
assessment
histologic
improve-
ment
(yes/no)
Skin B-cell
depletion
Smith et al. 8 Open label,
uncontrolled 61 I m p r o v e d Y e s In 4
patients Stable Stable
Lafyatis et al. 15 Open label,
uncontrolled 6/12 1 Stable Yes Yes Stable Stable
Daoussis et al. 8
Open label,
randomized
controlled
12 2 Improved Yes Yes Improved Improved
Boselo et al. 9 Open label,
uncontrolled 6–36
1( 3
patients
receive a
second
cycle)
Improved Not
reported No Stable Improved
McGonagle
et al. 1C a s e r e p o r t — 2 N o t r e p o r t e d Not
reported — Improved Improved
Daoussis et al. 1 Case report 24 4 Improved Improved Yes Improved Improved
Yu 1 Case report — 1 Not reported Not
reported — Improved Improved
successful treatment of CYC-resistant SSc-associated ILD
was reported [31]. Finally, RTX seems to favourably aﬀect
ILD in the context of other systemic rheumatic diseases
such as the antisynthetase syndrome as indicated by several
reports [32, 33]. All the available published data regarding
the clinical eﬃcacy of RTX in SSc are summarized in Table 1.
4. Discussion
SSc is perhaps the most challenging disease for rheumatol-
ogists. So far treatment is based on nonspeciﬁc immuno-
s u p p r e s s i o n ,w i t ha g e n t ss u c ha sC Y C[ 1] or mycophenolate
mofetil [34], with modest results. RTX has been used with
varying degrees of success in most systemic autoimmune
diseases and this is why, one may argue that its eﬀect on
a severe, incurable systemic autoimmune disease such as
SSc, is worthwhile exploring. Furthermore, there is a strong
rationale for the use of RTX in SSc; an expanding body of
evidence from basic research points to the direction that
B-cells may be active players in the ﬁbrotic process. On
clinical grounds, until now, 43 patients with diﬀuse SSc
have been treated with RTX (available published data). What
conclusions can be made regarding the use of RTX in SSc?
F i r s to fa l l ,t h i sa g e n ts e e m st ob ew e l lt o l e r a t e di nS S c
since only few adverse events have been reported. But is
RTX clinically eﬀective in SSc? Based on the available clinical
evidence, deﬁnite conclusions cannot be drawn; however
results are encouraging. In 3 out of 4 studies skin thickening
signiﬁcantly improved and, even in the single study where
no clinical beneﬁt on skin thickening was found, histologic
improvement was documented. These data may suggest a
disease modifying role of RTX in skin ﬁbrosis.
The most fearful manifestation of SSc is lung disease
whichisnowadaystheleadingcauseofmortality.Theclinical
evidence on the eﬃcacy of RTX in SSc-associated ILD is
limited, since most patients recruited either did not have ILD
or had only very mild ILD. With the exception of our study,
the other 3 studies were not designed to test the potential
clinical eﬃcacy of RTX in SSc-associated ILD. Nevertheless,
in these three studies PFTs remained stable, even though
mostpatientshadearlydiseaseandthereforeweremostlikely
to exhibit declining PFTs during their followup. In our study,
a signiﬁcant improvement of lung function was reported
in contrast to other studies where PFTs remained stable at
6 months compared to baseline. We should note, however,
several diﬀerences in the design of the studies that could
potentiallyexplainthesediverseﬁndings.Intheotherstudies
mostpatientsdidnothaveILDincontrasttoourstudywhere
the presence of ILD was an inclusion criterion. Furthermore,
the higher dose of RTX used (4 × 375mg/m2 instead of 2 ×
1000mg), consecutive treatments, and the longer evaluation
period could also be potential explanations. The signiﬁcant
improvement in lung function tests observed in our study
indicates that RTX may favourably aﬀect SSc-associated
ILD. Long-term treatment with RTX may either improve or
stabilize lung function over time in patients with SSc. All 8
patients recruited in the treatment arm group of our study
remained on RTX treatment and received two additional
courses; their PFTs continued to improve during the second
year of followup [35].6 International Journal of Rheumatology
I fR T Xt u r n so u tt ob ea ne ﬀective treatment for
SSc, which could be the potential mechanisms of action?
Several possibilities exist. First, B-cells appear to be actively
involved in the ﬁbrotic process, as indicated by data derived
from both animal models and humans. Elimination of skin
inﬁltrating B-cells by RTX has been documented, albeit not
consistently. Taking into account that B-cell inﬁltration is
a prominent ﬁnding in lung biopsies from patients with
SSc-associated ILD, depletion of this population may be a
potential explanation for the clinical improvement. It would
therefore be of great interest to study the eﬀect of RTX on
lung disease at a histological level, but this may be inherently
diﬃcult and challenging. We have also recently shown that
RTX-induced improvement of skin ﬁbrosis associates with
a decrease in PDGFR phosphorylation (which corresponds
to activation) in scleroderma skin [36]. Finally, another
mechanism may involve indirect eﬀect(s) of RTX on other
cells, such as T cells [37].
Both experimental and clinical evidence regarding B-
cell depletion in SSc is encouraging and certainly points
to the direction that further exploration of its clinical
eﬃcacy is warranted. The best way forward would be a
multicenter, randomized, double blind, placebo-controlled
study. If such a study is performed we propose that it
should focus on ILD rather than skin disease and that
it should be designed in such a way, that patients are
treated for at least one year and evaluated thereafter; in
this way, a treatment eﬀect on ILD (if any) would be more
easily depicted. To our knowledge, up until now, no such
study has been registered. Interestingly, however, a phase II
study assessing the clinical eﬃcacy of RTX in SSc-associated
pulmonary arterial hypertension has already been launched
(http://clinicaltrials.gov/show/NCT01086540). Moreover, a
phase I study of MEDI-551 (mAb against CD19) has also
been launced (http://clinicaltrials.gov/show/NCT00946699).
We believe that a large-scale multicenter, randomized study
assessingthepotentialclinicaleﬃcacyofRTXinSScishighly
needed.
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